Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12188/28302| Title: | Once-weekly subcutaneous semaglutide use I GLP-1 naïve patients with type 2 diabetes in North Macedonia: real world data from the MIRAGE study. | Authors: | Milenkovikj, Tatjana Jovanovska Mishevska, Sasha Bitoska Mileva, Iskra Ahmeti, Irfan Chekorova Mitreva, Biljana |
Issue Date: | Apr-2023 | Conference: | Congress of the Central European Diabetes Association (CEDA) | Abstract: | Safety and efficacy of once weekly (OW) subcutaneous (s.c.) semaglutide in T2D patients has been established in phase 3 clinical trials. In North Macedonia, no real-world evidence studies were conducted so far to assess the use of once weekly (OW) semaglutide in routine clinical practice. | URI: | http://hdl.handle.net/20.500.12188/28302 |
| Appears in Collections: | Faculty of Medicine: Conference papers |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| OP 2 Abstracts_engl_CEDA_congress_2023.pdf | 1.82 MB | Adobe PDF | View/Open |
Page view(s)
49
checked on Nov 6, 2024
Download(s)
162
checked on Nov 6, 2024
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.